 |
|
RESEARCH
|
Research in the Wittrup group is predominantly
focused on the application of protein engineering
to the development of cancer therapeutics.
|
Tumor targeting
|
Development of
optimized proteins and protocols for selectively
delivering radiometals and toxins to tumor cells.
Lab Researchers: John Rhoden, Xiaosai Yao, Cary Opel, Byron Kwan, Dr. James Van Deventer, Katie Maass
Collaborators: John Frangioni, BIDMC, Jack Wands, Brown University, Michael Rosenblum, MD Anderson Cancer Center, Steve
Larson, MSKCC, and Paul Yazaki, City of Hope. |
| Engineered
Antibody EGFR Antagonist Cancer Therapeutics |
Structure/function & trafficking
studies of antibody antagonism of the epidermal
growth factor receptor, involved in many
cancers.
Lab Researchers: Nicole Yang, Seymour de Picciotto, Michael Santos
Collaborators: Doug
Lauffenburger, MIT, Forest White, MIT, and John
Kuriyan, UC Berkeley. |
Tumor Immunotherapy
|
Presentation of tumor antigens
to the immune system together with stimulatory
signals that mimic a pathogenic infection to
attempt to raise a protective immune response.
Engineering altered binding properties of
interleukin 2 to enhance T cell
signaling properties. Engineering altered antibody effector functions
Lab Researchers: Annie Gai, Jordi Mata-Fink, Tiffany Chen, Alice Tzeng, Eric Zhu
Collaborators: Jianzhu
Chen, MIT, Darrell Irvine, MIT, Doug
Lauffenburger, MIT, and Jeff Ravetch, Rockefeller University. |
top |
|
|
|
